8 results about "Systemic circulation" patented technology

Methods and apparatus disclosed herein relate to graphical representation of patient hemodynamic state. In various embodiments, one or more measured physiological parameters of a patient may be analyzed. Based on the analysis, a graphical user interface (GUI) may be rendered. The GUI may include a figure-eight schematic (222, 1222) that represents a circulatory system of the patient. The figure-eight schematic may include: a first loop (224, 1224) that represents pulmonary circulation of the patient; a second loop (226, 1226) that represents systemic circulation of the patient; and a central object (228, 1228) that connects the first and second loops represents a heart of the patient. In various embodiments, each of the first and second loops includes multiple arc fragments, with each arc fragment being shaped to convey one or more of the measured physiological parameters of the patient.

The embodiment of the application discloses a kind of vein bionics microfluidic chip and its preparation and application method of simulating multi-organ interconnection.The chip includes a chip main body, and its microfluid channel system integrates at least three organ simulation units: a lung simulation chamber for culturing lung cells to simulate upstream organs that can produce systemic effects;An upstream colon cancer cell culture chamber for three-dimensional culture of colon cancer cells to simulate tumor primary lesions;And a downstream liver cell culture chamber for three-dimensional co-culture of liver cells and vascular endothelial cells to simulate the target organ of liver, and the three simulation chambers are communicated with each other by a vein bionics microfluid network, which simulates the complex blood circulation system of human body (including pulmonary circulation and systemic circulation), can realize the signal molecule transmission between organs, and simulate the invasion and metastasis process of colon cancer cells to the target organ of liver via the circulatory system after being affected by upstream lung signals.

The present application relates to the technical field of medicine, and particularly relates to an anti-pulmonary fibrosis prodrug compound and a preparation method and application thereof. The prodrug compound is a novel prodrug, and the structure comprises: a) an active drug unit selected from pirfenidone and nintedanib; b) a lung targeting unit selected from diphenyl chloroiodonium salt and a mimic thereof 521; and c) a linker unit which is a responsive linkage sensitive to a biomarker specifically overexpressed in a pulmonary fibrosis microenvironment. The prodrug is stable in the systemic circulation and has no activity or low activity, and can be actively targeted to a pulmonary fibrosis lesion; under the specific stimulation of the PFM, the linker is broken, and the original drug molecule is accurately released, so that the concentration of the drug in the lesion site is significantly increased, the toxic side effects caused by systemic exposure are reduced, and the anti-pulmonary fibrosis effect is enhanced.

The present disclosure provides compositions and methods for the preparation and therapeutic use of vectorized antibodies, such as adeno-associated virus (AAV) vectors having viral genomes encoding one or more therapeutic antibodies or antibody fragments or antibody-like polypeptides having reduced stability outside of a tissue of interest. In some embodiments, the disclosure provides therapeutic antibodies comprising a sequence motif for increasing susceptibility of the therapeutic antibodies to protease degradation in systemic circulation. In some embodiments, the disclosure provides therapeutic antibodies comprising a variant Fc domain having reduced binding affinity to FcRn. The disclosure also provides use of the AAVs for the prevention and / or treatment of diseases and / or disorders of the central nervous system (CNS).

The application belongs to the technical field of medicine, and particularly relates to application of acacetin or 6-hydroxyflavone in preparation of anti-angina pectoris drugs, and aims to solve the problems of adverse reactions such as blood pressure drop, reflex tachycardia and the like caused by non-selective vasodilation of existing anti-angina pectoris drugs, wherein the drug improves myocardial blood supply by selectively dilating coronary vessels of the heart, wherein acacetin dilates coronary vessels of the heart by inhibiting cardiac coronary vessel myosin light chain kinase and activating myosin light chain phosphatase, and 6-hydroxyflavone dilates coronary vessels of the heart by inhibiting protein kinase C and enhancing myosin light chain phosphatase activity; and the acacetin or 6-hydroxyflavone significantly reduces the symptoms of myocardial ischemia of rats caused by isopropyl adrenaline, improves characteristic ECG abnormal changes of angina pectoris, does not affect heart rate and systemic blood pressure, and is safer, thereby providing a potential drug selection for anti-angina pectoris treatment.

This invention discloses a parameter identification method for a lumped parameter model of systemic circulation, belonging to the field of lumped parameter model technology. The method includes: constructing the state equation of the lumped parameter model of systemic circulation based on Kirchhoff's voltage and current laws to obtain the systemic circulation control equation; calculating the duration ratio of systolic to diastolic phases and stroke volume based on routine clinical measurement data, constructing classic aortic pressure and flow waveforms, and performing registration processing; calculating central venous pressure and flow based on routine clinical measurement data; and using the registered aortic inlet pressure and flow, central venous pressure and flow, and systemic circulation control equations to calculate the values ​​of each parameter in the parameter model. This invention, by periodically stretching the classic reference waveform, matches the waveform extreme values ​​with the patient's measured blood pressure and cardiac output, indirectly reconstructing the aortic inlet pressure and flow curve reflecting individual characteristics under non-invasive conditions, significantly improving the model's individualization and clinical compatibility.

A minimally invasive, small percutaneous mechanical circulatory support system delivers a pump transcatheterally to the heart, which actively reduces the burden on the left ventricular system by pumping blood from the left ventricle to the ascending aorta and then to the systemic circulation. The pump may include a tubular housing, a motor, an impeller configured to be rotated by the motor, and a distal tip of the pump. The tip may include a guidewire lumen having a curved and / or extended contour. The system may include an insertion tool having a tubular body and configured to receive the circulatory support device axially movable, and an introducer sheath configured to receive the insertion tool axially movable. A coupling allows for connection and disconnection between the insertion tool and the introducer sheath. The coupling may include a hexagonal portion for self-positioning and further for tactile feedback.

This invention discloses a systemic circulation venous simulation system, comprising a right ventricular simulation component, an arterial compliance simulation component, a venous vessel module, a damping module, a throttling valve, a collapsible venous segment, a venous compliance simulation component, a right atrial simulation component, a drive module, and a data acquisition module. The right ventricular simulation component simulates the pumping function of the right ventricle; the arterial compliance simulation component simulates the elastic energy storage characteristics of the arterial system; the venous vessel module includes a collecting chamber, a superior vena cava return vessel, an inferior vena cava return vessel, and a vena cava confluence conduit; the collapsible venous segment prevents excessive negative pressure in the venous system; the venous compliance simulation component reduces the impact of right atrial pressure fluctuations on the venous vessels; and the right atrial simulation component simulates the right atrial filling state through internal volume changes. This simulation system can be used for in vitro testing of vena cava intervention devices.